A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome

J Fastman, J Foss-Feig, Y Frank, D Halpern, H Harony-Nicolas, C Layton, S Sandin, P Siper, L Tang, P Trelles, J Zweifach, J D Buxbaum, A Kolevzon, J Fastman, J Foss-Feig, Y Frank, D Halpern, H Harony-Nicolas, C Layton, S Sandin, P Siper, L Tang, P Trelles, J Zweifach, J D Buxbaum, A Kolevzon

Abstract

Background: Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused by haploinsufficiency of the SHANK3 gene and characterized by global developmental delays, deficits in speech and motor function, and autism spectrum disorder (ASD). Monogenic causes of ASD such as PMS are well suited to investigations with novel therapeutics, as interventions can be targeted based on established genetic etiology. While preclinical studies have demonstrated that the neuropeptide oxytocin can reverse electrophysiological, attentional, and social recognition memory deficits in Shank3-deficient rats, there have been no trials in individuals with PMS. The purpose of this study is to assess the efficacy and safety of intranasal oxytocin as a treatment for the core symptoms of ASD in a cohort of children with PMS.

Methods: Eighteen children aged 5-17 with PMS were enrolled. Participants were randomized to receive intranasal oxytocin or placebo (intranasal saline) and underwent treatment during a 12-week double-blind, parallel group phase, followed by a 12-week open-label extension phase during which all participants received oxytocin. Efficacy was assessed using the primary outcome of the Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) subscale as well as a number of secondary outcome measures related to the core symptoms of ASD. Safety was monitored throughout the study period.

Results: There was no statistically significant improvement with oxytocin as compared to placebo on the ABC-SW (Mann-Whitney U = 50, p = 0.055), or on any secondary outcome measures, during either the double-blind or open-label phases. Oxytocin was generally well tolerated, and there were no serious adverse events.

Limitations: The small sample size, potential challenges with drug administration, and expectancy bias due to relying on parent reported outcome measures may all contribute to limitations in interpreting results.

Conclusion: Our results suggest that intranasal oxytocin is not efficacious in improving the core symptoms of ASD in children with PMS. Trial registration NCT02710084.

Keywords: ASD; Autism spectrum disorder; Oxytocin; PMS; Phelan-McDermid syndrome; Shank3.

Conflict of interest statement

AK receives research support from AMO Pharma and consults to Acadia, Alkermes, and Ovid Therapeutics. JDB has a shared patent with Mount Sinai for IGF-1 in Phelan-McDermid syndrome. No other authors have competing interests to disclose.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Mean scores on the Aberrant Behavior Checklist Social Withdrawal subscale across study visits. Bars represent standard error

References

    1. Alvares GA, Quintana DS, Whitehouse AJ. Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder. Autism Res. 2017;10(1):25–41. doi: 10.1002/aur.1692.
    1. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485–491.
    1. Aman MG, Singh NN. Supplement to Aberrant Behavior Checklist manual. East Aurora: Slosson Educational Publications; 1994.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM-5®); American Psychiatric Publishing: Lansing. USA: MI; 2013.
    1. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3(1):16. doi: 10.1186/2040-2392-3-16.
    1. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA. 2010;107(9):4389–4394. doi: 10.1073/pnas.0910249107.
    1. Aoki Y, Yahata N, Watanabe T, Takano Y, Kawakubo Y, Kuwabara H, Iwashiro N, Natsubori T, Inoue H, Suga M, Takao H, Sasaki H, Gonoi W, Kunimatsu A, Kasai K, Yamasue H. Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism. Brain. 2014;137(Pt 11):3073–3086. doi: 10.1093/brain/awu231.
    1. Aoki Y, Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Takao H, Kawakubo Y, Kasai K, Yamasue H. Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial. Mol Psychiatry. 2015;20(4):447–453. doi: 10.1038/mp.2014.74.
    1. Bartz JA, Nitschke JP, Krol SA, Tellier PP. Oxytocin selectively improves empathic accuracy: a replication in men and novel insights in women. Biol Psychiatry Cogn Neurosci Neuroimaging 2019;4(12):1042–1048.
    1. Baskerville TA, Douglas AJ. Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders. CNS Neurosci Ther. 2010;16(3):e92–123. 10.1111/j.1755-5949.2010.00154.x.
    1. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron. 2008;58(4):639–650. doi: 10.1016/j.neuron.2008.04.009.
    1. Benner S, Aoki Y, Watanabe T, Endo N, Abe O, Kuroda M, Kuwabara H, Kawakubo Y, Takao H, Kunimatsu A, Kasai K, Bito H, Kakeyama M, Yamasue H. Neurochemical evidence for differential effects of acute and repeated oxytocin administration. Mol Psychiatry. 2021;26(2):710–720. doi: 10.1038/s41380-018-0249-4.
    1. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30(3):237–243. doi: 10.1023/A:1005596502855.
    1. Boeckers TM. The postsynaptic density. Cell Tissue Res. 2006;362:409–422. doi: 10.1007/s00441-006-0274-5.
    1. Bonaglia MC, Giorda R, Mani E, Aceti G, Anderlid BM, Barconcini A, Pramparo T, Zuffardi O. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet. 2006;10:822–828. doi: 10.1136/jmg.2005.038604.
    1. Bonaglia MC, Giorda R, Beri S, De Agostini C, et al. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genet. 2011;7(7).
    1. Bozdagi, O, Sakurai, T, Papapetrou, D, Wang, X, Dickstein, DL, Takahashi, N, Kajiwara, Y, Yang, M, Katz, AM, Scattoni, ML, Harris, MJ, Saxena, R, Silverman, JL, Crawley, JN, Zhou, Q, Hof, PR, Buxbaum JD. Halpoinsufficiency of the autism-associated SHANK3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism. 2010;1–15.
    1. Braida D, et al. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior zebrafish. Psychopharmacology. 2012;220:319–330. doi: 10.1007/s00213-011-2482-2.
    1. Brown EC, Aman MG, Havercamp SM. Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Res Dev Disabil. 2002;23(1):45–60. doi: 10.1016/S0891-4222(01)00091-9.
    1. Cai Q, Feng L, Yap KZ. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry Clin Neurosci. 2018;72(3):140–151. doi: 10.1111/pcn.12627.
    1. Chang SW, Platt ML. Oxytocin and social cognition in rhesus macaques: implications for understanding and treating human psychopathology. Brain Res. 2014;1580:57–68. doi: 10.1016/j.brainres.2013.11.006.
    1. De Dreu CK, Greer LL, Handgraaf MJ, Shalvi S, Van Kleef GA, Baas M, Ten Velden FS, Van Dijk E, Feith SW. The neuropeptide oxytocin regulates parochial altruism in intergroup conflict among humans. Science. 2010;328(5984):1408–1411. doi: 10.1126/science.1189047.
    1. Di Simplicio M, Massey-Chase R, Cowen PJ, Harmer CJ. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol. 2009;23(3):241–248. doi: 10.1177/0269881108095705.
    1. Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry. 2009;65(9):728–731. doi: 10.1016/j.biopsych.2008.10.011.
    1. Domes G, Lischke A, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology. 2010;35(1):83–93. doi: 10.1016/j.psyneuen.2009.06.016.
    1. Domes G, Heinrichs M, Kumbier E, Grossmann A, Hauenstein K, Herpertz SC. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol Psychiatry. 2013;74(3):164–171. doi: 10.1016/j.biopsych.2013.02.007.
    1. Domes G, Kumbier E, Heinrichs M, Herpertz SC. Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with asperger syndrome. Neuropsychopharmacology. 2014;39(3):698–706. doi: 10.1038/npp.2013.254.
    1. Dumais KM, Veenema AH. Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior. Front Neuroendocrinol. 2016;40:1–23. doi: 10.1016/j.yfrne.2015.04.003.
    1. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39(1):25–27. doi: 10.1038/ng1933.
    1. Dunn, W. Sensory Profile. The Psychological Corporation. 1999.
    1. Farmer C, Golden C, Thurm A. Concurrent validity of the differential ability scales, second edition with the Mullen Scales of Early Learning in young children with and without neurodevelopmental disorders. Child Neuropsychol. 2016;22(5):556–69.
    1. Fenson L, Dale PS, Reznick JS, Thal DJ, Bates E, Hartung JP, Pethick S, Reilly JS. MacArthur communicative development inventories: user’s guide and technical manual. Baltimore: Paul H. Brokes Publishing Co.; 1993.
    1. Fenson, L, Marchman, VA, Thal, DJ, Dale, PS, Reznick, JS, Bates, E. MacArthur-Bates communicative development inventories: user’s guide and technical manual (2nd ed.) Baltimore: Paul H. Brooks Publishing Co. 2007.
    1. Fischer-Shofty M, Shamay-Tsoory SG, Levkovitz Y. Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls. Front Neurosci. 2018;7:127.
    1. Gabor CS, Phan A, Clipperton-Allen AE, Kavaliers M, Choleris E. Interplay of oxytocin, vasopressin, and sex hormones in the regulation of social recognition. Behav Neurosci. 2012;126(1):97–109. doi: 10.1037/a0026464.
    1. Gimple G, Fahrenholz F. The Oxytocin Receptor System: Structure, Function, and Regulation. Physiol Rev. 2001;81(2):629–683. doi: 10.1152/physrev.2001.81.2.629.
    1. Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas MV, Eilbott JA, Zagoory-Sharon O, Leckman JF, Feldman R, Pelphrey KA. Oxytocin enhances brain function in children with autism. Proc Natl Acad Sci USA. 2013;110(52):20953–20958. doi: 10.1073/pnas.1312857110.
    1. Guastella AJ, Mitchell PB, Mathews F. Oxytocin enhances the encoding of positive social memories in humans. Biol Psychiatry. 2008;64(3):256–258. doi: 10.1016/j.biopsych.2008.02.008.
    1. Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry. 2008;63(1):3–5. doi: 10.1016/j.biopsych.2007.06.026.
    1. Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015;56(4):444–452. doi: 10.1111/jcpp.12305.
    1. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692–694. doi: 10.1016/j.biopsych.2009.09.020.
    1. Guo B, Chen J, Chen Q, Ren K, Feng D, Mao H, Yao H, Yang J, Liu H, Liu Y, Jia F, Qi C, Lynn-Jones T, Hu H, Fu Z, Feng G, Wang W, Wu S. Anterior cingulate cortex dysfunction underlies social deficits in Shank3 mutant mice. Nat Neurosci. 2019;22(8):1223–1234. doi: 10.1038/s41593-019-0445-9.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology—Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extra-mural Research Programs. 1976;218–222.
    1. Harony-Nicolas H, De Rubeis S, Kolevzon A, Buxbaum JD. Phelan McDermid syndrome: from genetic discoveries to animal models and treatment. J Child Neurol. 2015;30(14):1861–1870. doi: 10.1177/0883073815600872.
    1. Harony-Nicolas H, Kay M, du Hoffmann J, Klein ME, Bozdagi-Gunal O, Riad M, Daskalakis NP, Sonar S, Castillo PE, Hof PR, Shapiro ML, Baxter MG, Wagner S, Buxbaum JD. Oxytocin improves behavioral and electrophysiological deficits in a novel Shank3-deficient rat. Elife. 2017;6:e18904.
    1. Hettmansperger T, McKean J. Robust Nonparametric Statistical Methods, Second Edition. 2nd ed. 2010.
    1. Jacot-Descombes S, Keshav NU, Dickstein DL, Wicinski B, Janssen WGM, Hiester LL, Sarfo EK, Warda T, Fam MM, Harony-Nicolas H, Buxbaum JD, Hof PR, Varghese M. Altered synaptic ultrastructure in the prefrontal cortex of Shank3-deficient rats. Mol Autism. 2020;11(1):89. doi: 10.1186/s13229-020-00393-8.
    1. Javed S, Selliah T, Lee YJ, Huang WH. Dosage-sensitive genes in autism spectrum disorders: from neurobiology to therapy. Neurosci Biobehav Rev. 2020;118:538–567. doi: 10.1016/j.neubiorev.2020.08.009.
    1. Kéri S, Benedek G. Oxytocin enhances the perception of biological motion in humans. Cogn Affect Behav Neurosci. 2009;9(3):237–241. doi: 10.3758/CABN.9.3.237.
    1. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature. 1992;356(6369):526–529. doi: 10.1038/356526a0.
    1. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435(7042):673–676. doi: 10.1038/nature03701.
    1. Kubota Y, et al. Structure and expression of the mouse oxytocin receptor gene. Mol Cell Endocrinol. 1996;124:25–32. doi: 10.1016/S0303-7207(96)03923-8.
    1. Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, Lumbroso S, Giuliano F, Stordeur C, Depienne C, Mouzat K, Pinto D, Howe J, Lemière N, Durand CM, Guibert J, Ey E, Toro R, Peyre H, Mathieu A, Amsellem F, Rastam M, Gillberg IC, Rappold GA, Holt R, Monaco AP, Maestrini E, Galan P, Heron D, Jacquette A, Afenjar A, Rastetter A, Brice A, Devillard F, Assouline B, Laffargue F, Lespinasse J, Chiesa J, Rivier F, Bonneau D, Regnault B, Zelenika D, Delepine M, Lathrop M, Sanlaville D, Schluth-Bolard C, Edery P, Perrin L, Tabet AC, Schmeisser MJ, Boeckers TM, Coleman M, Sato D, Szatmari P, Scherer SW, Rouleau GA, Betancur C, Leboyer M, Gillberg C, Delorme R, Bourgeron T. Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014;10(9):e1004580. 10.1371/journal.pgen.1004580.
    1. Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry. 2016;79(3):243–250. doi: 10.1016/j.biopsych.2015.05.003.
    1. Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659–685. doi: 10.1007/BF02172145.
    1. Lord C, Rutter M, DiLavore PC, Risi S, Gotham K, Bishop D. The autism diagnostic observation schedule, second edition (ADOS-2) manual (Part 1): Modules 1–4. Torrance, CA: Western Psychological Services; 2012.
    1. Mullen E. Mullen scales of early learning. Circle Pines: American Guidance Service; 1989.
    1. Mitre M, et al. A distributed network for social cognition enriched for oxytocin receptors. J Neurosci. 2016;36:2517–2535. doi: 10.1523/JNEUROSCI.2409-15.2016.
    1. Monteiro P, Feng G. SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 2017;18(3):147–157. doi: 10.1038/nrn.2016.183.
    1. Mossink B, Negwer M, Schubert D, Nadif Kasri N. The emerging role of chromatin remodelers in neurodevelopmental disorders: a developmental perspective. Cell Mol Life Sci. 2020.
    1. Pagani M, De Felice A, Montani C, Galbusera A, Papaleo F, Gozzi A. Acute and repeated intranasal oxytocin differentially modulate brain-wide functional connectivity. Neuroscience. 2020;445:83–94. doi: 10.1016/j.neuroscience.2019.12.036.
    1. Parker KJ, Oztan O, Libove RA, Sumiyoshi RD, Jackson LP, Karhson DS, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, Garner JP, Hardan AY. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci USA. 2017;114(30):8119–8124. doi: 10.1073/pnas.1705521114.
    1. Petrovic P, Kalisch R, Singer T, Dolan RJ. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci. 2008;28(26):6607–6615. doi: 10.1523/JNEUROSCI.4572-07.2008.
    1. Quintana DS, Alvares GA, Hickie IB, Guastella AJ. Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model. Neurosci Biobehav Rev. 2015;49:182–192. doi: 10.1016/j.neubiorev.2014.12.011.
    1. Reichova A, Bacova Z, Bukatova S, Kokavcova M, Meliskova V, Frimmel K, Ostatnikova D, Bakos J. Abnormal neuronal morphology and altered synaptic proteins are restored by oxytocin in autism-related SHANK3 deficient model. Mol Cell Endocrinol. 2020;518:110924. doi: 10.1016/j.mce.2020.110924.
    1. Richard P, Moos F, Freund-Mercier MJ. Central effects of oxytocin. Physiol Rev. 1991;71(2):331–370. doi: 10.1152/physrev.1991.71.2.331.
    1. Rimmele U, Hediger K, Heinrichs M, Klaver P. Oxytocin makes a face in memory familiar. J Neurosci. 2009;29(1):38–42. doi: 10.1523/JNEUROSCI.4260-08.2009.
    1. Savaskan E, Ehrhardt R, Schulz A, Walter M, Schächinger H. Post-learning intranasal oxytocin modulates human memory for facial identity. Psychoneuroendocrinology. 2008;33(3):368–374. doi: 10.1016/j.psyneuen.2007.12.004.
    1. Sikich L, on behalf of ACE SOARS Network, (2019). SOARS-B: A large, phase II RCT of daily oxytocin in ASD for enhancing reciprocal social behaviors. 66th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 19th, 2019, Chicago, IL.
    1. Song TJ, Lan XY, Wei MP, Zhai FJ, Boeckers TM, Wang JN, Yuan S, Jin MY, Xie YF, Dang WW, Zhang C, Schön M, Song PW, Qiu MH, Song YY, Han SP, Han JS, Zhang R. Altered Behaviors and Impaired Synaptic Function in a Novel Rat Model With a Complete Shank3 Deletion. Front Cell Neurosci. 2019;13:111. doi: 10.3389/fncel.2019.00111.
    1. Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, Schwartz L, Frank Y, Wang AT, Cai G, Parkhomenko E, Halpern D, Grodberg D, Angarita B, Willner JP, Yang A, Canitano R, Chaplin W, Betancur C, Buxbaum JD. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism. 2013;4(1):18. doi: 10.1186/2040-2392-4-18.
    1. Soorya L, Leon J, Trelles MP, Thurm A. Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome. Clin Neuropsychol. 2018;32(7):1226–1255. doi: 10.1080/13854046.2017.1413211.
    1. Sparrow, SS, Balla, DA, and Cicchetti, DV, Vineland adaptive behaviour scales: a revision of the vineland social maturity scale by Edgar A. Doll. Circle-Pines, MN: American Guidance Service. 1984.
    1. Tachibana M, Kagitani-shimono K, Mohri I, et al. Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2013;23(2):123–127. doi: 10.1089/cap.2012.0048.
    1. Theodoridou A, Rowe AC, Penton-Voak IS, Rogers PJ. Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. Horm Behav. 2009;56(1):128–132. doi: 10.1016/j.yhbeh.2009.03.019.
    1. Unkelbach C, Guastella AJ, Forgas JP. Oxytocin selectively facilitates recognition of positive sex and relationship words. Psychol Sci. 2008;19(11):1092–1094. doi: 10.1111/j.1467-9280.2008.02206.x.
    1. Varghese M, Keshav N, Jacot-Descombes S, Warda T, Wicinski B, Dickstein DL, Harony-Nicolas H, De Rubeis S, Drapeau E, Buxbaum JD, Hof PR. Autism spectrum disorder: neuropathology and animal models. Acta Neuropathol. 2017;134(4):537–566. doi: 10.1007/s00401-017-1736-4.
    1. Veening JG, Olivier B. Intranasal administration of oxytocin: behavioral and clinical effects, a review. Neurosci Biobehav Rev. 2013;37(8):1445–65. 10.1016/j.neubiorev.2013.04.012.
    1. Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Aoki Y, Takao H, Kawakubo Y, Kamio Y, Kato N, Miyashita Y, Kasai K, Yamasue H. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiat. 2014;71(2):166–175. doi: 10.1001/jamapsychiatry.2013.3181.
    1. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin. 1945;6:80–83. doi: 10.2307/3001968.
    1. Yang M, Bozdagi O, Scattoni ML, et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci. 2012;32(19):6525–6541. doi: 10.1523/JNEUROSCI.6107-11.2012.
    1. Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21(9):1225–1231. doi: 10.1038/mp.2015.162.
    1. Zak PJ, Kurzban R, Matzner WT. Oxytocin is associated with human trustworthiness. Horm Behav. 2005;48(5):522–527. doi: 10.1016/j.yhbeh.2005.07.009.
    1. Zatkova M, Reichova A, Bacova Z, Strbak V, Kiss A, Bakos J. Neurite outgrowth stimulated by oxytocin is modulated by inhibition of the calcium voltage-gated channels. Cell Mol Neurobiol. 2018;38(1):371–378. doi: 10.1007/s10571-017-0503-3.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi